Empowered Patient Podcast

Dr. Dan Gold is the President and CEO of MEI Pharma and is tackling non-Hodgkin's B cell lymphoma to bring a therapy to patients minimizing the toxicities that are associated with current treatments. Their drug candidate zandelisib is a P13K delta inhibitor. It is being studied in lymphoma in B cells to determine if this is a way to block signaling and diminish the malignant capacity of the B cell. Dan explains, "We sort of think of lymphoma in two flavors. it's either a more chronic disease, or it's a more aggressive disease, and then there is sort of a spectrum that spans that. In the less aggressive, we call it indolent diseases, the patients will live with these cancers for many, many years. " "So for the cancers that we treat most commonly or that we're studying most commonly, they're more of the indolent variety. It is interesting because the fact that it's indolent, the patients will respond to therapies. But, eventually, the efficacy of that therapy will wane, and they'll need something else. But ther